What are the future development trends for Hong Kong’s pharmaceutical licensing regime?

Hong Kong’s pharmaceutical licensing system is moving towards greater scientific rigour, international alignment and comprehensive coverage. Key future trends include the following. First, risk-based regulation will be further strengthened, with regulatory resources increasingly focused on high-risk products and activities. Second, alignment with international standards will deepen. For example, internationally accepted standards will be adopted comprehensively in areas such as medical devices and clinical trials. Third, the application and regulation of new technologies will become a focus. Regulatory frameworks for advanced therapy products (ATPs), such as cell and gene therapies, are being developed, while clearer guidance is also expected on telemedicine and the use of artificial intelligence in the pharmaceutical sector. Fourth, regulatory coordination and interoperability for medicines and medical devices within the Greater Bay Area will remain a long-term trend, with policies facilitating access for Hong Kong and Macao residents potentially being expanded. For the industry, this means the need for continuous learning and ongoing improvements in compliance to adapt to an increasingly stringent and complex regulatory environment, while also creating opportunities to access broader markets.